Gout – what are the treatment options?

Bibliography

• Schlesinger N. Management of acute and chronic gouty arthritis: present state-of-the-art. Drugs 2004;64:2399-416
   PubMed Web of Science ®Google Scholar
• Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-24
   PubMed Web of Science ®Google Scholar
• Schlesinger N. Reassessing the safety of intravenous and compounded injectable colchicine in acute gout treatment. EDOS 2007;6:625-9
   Google Scholar
• Schlesinger N, Moore DF, Sun JD, Schumacher HR. A survey of current evaluation and treatment of gout. J Rheumatol 2006;33:2050-2
   PubMed Web of Science ®Google Scholar
• Petersel D, Schlesinger N. Treatment of acute gout in hospitalized patients. J Rheumatol 2007;34:1566-8
   PubMed Web of Science ®Google Scholar
• Bellamy N, Gilbert JR, Brooks PM, et al. A survey of current prescribing practices of anti-inflammatory and urate lowering drugs in gouty arthritis in the Province of Ontario. J Rheumatol 1988;15:1841-71
   PubMed Web of Science ®Google Scholar
• Bellamy N, Brooks PM, Gilbert RJ, et al. Survey of current prescribing practices of anti-inflammatory and urate lowering drugs in gouty arthritis in New South Wales and Queensland. Med J Aust 1989;151:537-51
   Google Scholar
• Stuart RA, Gow PJ, Bellamy N, et al. A survey of current prescribing practices of anti-inflammatory and urate-lowering drugs in gouty arthritis. NZ Med J 1991;104:115-17
   PubMedGoogle Scholar
• Rozenberg S, Lang T, Laatar A, et al. Diversity of opinions on the management of gout in France. A survey of 750 rheumatologists. Rev Rhum Engl Ed 1996;63:255-61
   PubMedGoogle Scholar
• Weede RP. Poison in the Pot: The Legacy of Lead. Southern Illinois University Press: Carbondale and Edwardsville, 1984. p. 83
   Google Scholar
• Katzung BG. Basic and Clinical Pharmacology. In: Katzung BG, editor, Norwalk: Apleton & Lange, 1995. p. 536-59
   Google Scholar
• Roberge CJM, Gaudry R, de Medicis A, et al. Crystal-induced neutrophil activation IV. Specific inhibition of tyrosine phosphorylation by colchicine. J Clin Invest 1993;92:1722-9
   PubMedGoogle Scholar
• Cronstein BN, Molad Y, Reibman J, et al. Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. J Clin Invest 1995;96:994-1002
   PubMed Web of Science ®Google Scholar
• Spilberg I, Mandell B, Mehta J, et al. Mechanism of action of colchicine in acute urate crystal-induced arthritis. J Clin Invest 1979;64:775-80
   PubMed Web of Science ®Google Scholar
• Martinon F, Petrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006;440:237-41
   PubMed Web of Science ®Google Scholar
• Schlesinger N, Schumacher HR Jr, Catton M, Maxwell L. Colchicine therapy for acute gout. Review: cochrane international collaboration. Cochrane Database Syst Rev 2006;4:CD006190
   Google Scholar
• Ahern MJ, Reid C, Gordon TP. Does colchicine work? Results of the first controlled study in gout. Aust NZ J Med 1987;17:301-4
   PubMedGoogle Scholar
• Macleod JG, Phillips L. Hypersensitivity to colchicine. Ann Rheum Dis 1947;6:224-9
   Web of Science ®Google Scholar
• British Medical Association, Royal Pharmaceutical Society of Great Britain. British national formulary. No. 44. London: BMA, RPS, 2002. p. 500
   Google Scholar
• Jayaprakash V, Ansell G, Galler D. Colchicine overdose: the devil is in the detail. NZ Med J 2007;120:1248
   Google Scholar
• Varughese G, Varughese A, Tahrani A. Colchicine: time to rethink. NZ Med J 2007;120:e31
   Google Scholar
• Morris I, Varughese G, Mattingly P. Colchicine in acute gout. BMJ 2003;327:1275-6
   PubMed Web of Science ®Google Scholar
• Paulus HE, Schlosstein LH, Godfrey RC, et al. Prophylactic colchicine therapy in intercritical gout. Arthritis Rheum 1987;17:609-14
   Web of Science ®Google Scholar
• Laine L. Nonsteroidal anti-inflammatory drug gastropathy. Gastrointest Endosc Clin N Am 1996;6:489-504
   PubMedGoogle Scholar
• Emmerson BT. The management of gout. N Engl J Med 1996;334:445-1
   PubMed Web of Science ®Google Scholar
• Smythe CJ, Percy JS. Comparison of indomethacin and phenylbutazone in acute gout. Ann Rheum Dis 1973;32:351-3
   PubMedGoogle Scholar
• Rousti A, Vainio U. Treatment of acute gouty arthritis with proquazone and indomethacin. A comparative double-blind trial. Scan J Rheumatol 1978;(Suppl 21):15-7
   Google Scholar
• Altman RD, Honig S, Levin JM, et al. Ketoprofen versus indomethacin in patients with acute gouty arthritis: a multicenter, double blind comparative study. J Rheumatol 1988;15:1422-6
   PubMed Web of Science ®Google Scholar
• Weiner GI, White SR, Weitzner RI, et al. Double blind study of phenoprofen versus phenylbutazone in acute gouty arthritis. Arthritis Rheum 1979;22:425-6
   PubMedGoogle Scholar
• Shrestha M, Morgan DL, Moreden JM, et al. Randomized double-blind comparison of the analgesic efficacy of intramuscular ketorolac and oral indomethacin in the treatment of acute gouty arthritis. Ann Emerg Med 1995;26:682-6
   PubMed Web of Science ®Google Scholar
• Macagno A, Di Giorgio E, Romanowicz A. Effectiveness of etodolac (Lodine) compared with naproxen in patients with acute gout. Curr Med Res Opin 1991;12:423-9
   PubMedGoogle Scholar
• Schumacher HR, Boice J, Dahikh DI, et al. Randomized double blind trial of etoricoxib and indomethacin in treatment of acute gouty arthritis. BMJ 2002;324:1488-92
   PubMed Web of Science ®Google Scholar
• Rubin BR, Burton R, Navarra S, et al. Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. Arthritis Rheum 2004;50:598-606
   PubMed Web of Science ®Google Scholar
• Willburger RE, Mysler E, Derbot J. et al. Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout. Rheumatology 2007; 46:1126-32
   PubMed Web of Science ®Google Scholar
• Fernandez C, Noguera R, Gonzalez JA, et al. Treatment of acute attacks of gout with small doses of intraarticular triamcinolone acetonide. J Rheumatol 1999;26:2285-6
   PubMed Web of Science ®Google Scholar
• Groff GD, Franck WA, Raddatz DA. Systemic steroid therapy for acute gout: a clinical trial and review of the literature. Semin Arthritis Rheum 1990;19:329-36
   PubMed Web of Science ®Google Scholar
• Alloway JA, Moriarty MJ, Hoogland YT, et al. Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis. J Rheumatol 1993;20:111-13
   PubMed Web of Science ®Google Scholar
• Janssens HJ, Janssen M, van de Lisdonk EH, et al. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet 2008;371:1854-60
   PubMed Web of Science ®Google Scholar
• Getting SJ, Christian HC, Flower RJ, et al. Activation of melanocortin type 3 receptor as a molecular mechanism for adrenocorticotropic hormone efficacy in gouty arthritis. Arthritis Rheum 2002;46:2765-75
   PubMed Web of Science ®Google Scholar
• Getting SJ, Lam CW, Chen AS, et al. Melanocortin 3 receptors control crystal-induced inflammation. FASEB J 2006;20:2234-41
   PubMed Web of Science ®Google Scholar
• Ritter J, Kerr LD, Valeriano-Marcet J, et al. ACTH revisited: effective treatment for acute crystal induced synovitis in patients with multiple medical problems. J Rheumatol 1994;21:696-9
   PubMed Web of Science ®Google Scholar
• Axelrod D, Preston S. Comparison of parenteral adrenocorticotropic hormone with oral indomethacin in the treatment of acute gout. Arthritis Rheum 1988;31:803-5
   PubMed Web of Science ®Google Scholar
• Seigel LB, Alloway JA, Nashel DJ. Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of gouty arthritis. J Rheumatol 1994;21:1325-7
   PubMedGoogle Scholar
• Borstad GC, Bryant LR, Abel MP, et al. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 2004;31:2429-32
   PubMed Web of Science ®Google Scholar
• Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353:2450-61
   PubMed Web of Science ®Google Scholar
• Wallace SL, Singer JZ, Duncan GJ, et al. Renal function predicts colchicine toxicity: guidelines for the prophylactic use of colchicine in gout. J Rheumatol 1991;18:264-9
   PubMed Web of Science ®Google Scholar
• Ducloux D, Schuller V, Bresson-Vautrin C, et al. Colchicine myopathy in renal transplant recipients on cyclosporin. Nephrol Dial Transplant 1997;12:2389-92
   PubMedGoogle Scholar
• Baker SK, Goodwin S, Sur M, et al. Cytoskeletal myotoxicity from simvastatin and colchicine. Muscle Nerve 2004;30:799-802
   PubMedGoogle Scholar
• Hung IF, Wu AK, Cheng VC, et al. Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study. Clin Infect Dis 2005;41:291-300
   PubMed Web of Science ®Google Scholar
• Hollingworth P, Reardon JA, Scott JT. Acute gout during hypouricaemic therapy: prophylaxis with colchicine. Ann Rheum Dis 1980;39:529
   PubMedGoogle Scholar
• Templeton JS. Azapropazone or allopurinol in the treatment of chronic gout and/or hyperuricaemia. A preliminary report. Br J Clin Pract 1982;36:353-8
   PubMedGoogle Scholar
• Mikuls TR, Farrar JT, Bilker WB, et al. Gout epidemiology: results from the UK General Practice Research Database, 1990-1999. Ann Rheum Dis 2005;64:267-72
   PubMed Web of Science ®Google Scholar
• McGonagle D, Tan AL, Shankaranarayana S, et al. Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra. Ann Rheum Dis 2007;66:1683-4
   PubMed Web of Science ®Google Scholar
• Hoffman HM, Throne ML, Amar NJ, et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 2008;58:2443-52
   PubMed Web of Science ®Google Scholar
• Perez-Ruiz F, Lioté F. Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout? Arthritis Rheum 2007;57:1324-8
   PubMed Web of Science ®Google Scholar
• Pascual E, Sivera F. Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout. Ann Rheum Dis 2007;66:1056-8
   PubMed Web of Science ®Google Scholar
• Perez-Ruiz F, Calabozo M, Pijoan JI, et al. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002;47:356-60
   PubMed Web of Science ®Google Scholar
• Perez-Ruiz F, Martin I, Canteli B. Ultrasonographic measurement of tophi as an outcome measure for chronic gout. J Rheumatol 2007;34:1888-93
   PubMed Web of Science ®Google Scholar
• Choi HK, Curhan G. Gout: epidemiology and lifestyle choices. Curr Opin Rheumatol 2005;17:341-5
   PubMed Web of Science ®Google Scholar
• Rundles RW, Metz EN, Silberman HR. Allopurinol in the treatment of gout. 1966;64:229-258
   Google Scholar
• Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, et al. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 1998;57:545-9
   PubMed Web of Science ®Google Scholar
• Reinders MK, Haggsma C, Jansen TL, et al. A randomized-controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300 – 600 mg/day versus benzbromarone 100 – 200 mg/day in patients with gout. Ann Rheum Dis 2008;doi:10.1136/ard.2008.091462
   Google Scholar
• Perez-Ruiz F, Calabozo M, Fernandez-Lopez MJ, et al. Treatment of chronic gout in patients with renal function impairment. An open, randomized, actively controlled. J Clin Rheumatol 1999;5:49-55
   PubMed Web of Science ®Google Scholar
• Halevy S, Ghislain PD, Mockenhaupt M, et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 2007;58:25-32
   PubMedGoogle Scholar
• Chiou CC, Yang LC, Hung SI, et al. Clinicopathological features and prognosis of drug rash with eosinophilia and systemic symptoms: a study of 30 cases in Taiwan. J Eur Acad Dermatol Venereol 2008;22:1044-9
   PubMed Web of Science ®Google Scholar
• Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984;76:47-56
   PubMed Web of Science ®Google Scholar
• Dalbeth N, Kumar S, Stamp L, et al. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol 2006;33:1646-50
   PubMed Web of Science ®Google Scholar
• Perez-Ruiz F, Hernando I, Villar I, et al. Correction of allopurinol dosing should be based on clearance of creatinine, but not plasma creatinine levels. Another insight to allopurinol-related toxicity. J Clin Rheumatol 2005;11:129-33
   PubMedGoogle Scholar
• Vazquez-Mellado J, Meoño Morales E, Pacheco-Tena C, et al. Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis 2001;60:981-3
   PubMed Web of Science ®Google Scholar
• Hung SI, Chungwh LIOU, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Nat Acad Sci 2005;102:4134-9
   PubMed Web of Science ®Google Scholar
• Jansen TL, Reinders MK, Van Roon EN, et al. Benzbromarone withdrawn form the European market: another case of ‘absence of evidence is evidence of absence’? Clin Exp Rheumatol 2004;22:651
   PubMed Web of Science ®Google Scholar
• Perez-Ruiz F, Gomez-Ullate P, Amenabar JJ, et al. Long-term efficacy of hyperuricemia treatment in renal trasplant patients. Nephrol Dial Transplant 2003;18:603-6
   PubMedGoogle Scholar
• Takano Y, Hase-Aoki K, Horiuchi H, et al. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci 2005;76:1835-47
   PubMed Web of Science ®Google Scholar
• Perez-Ruiz F, Dalbeth N, Schlesinger N. Febuxostat, a novel drug for the treatment of hyperuricemia of gout. Future Rheumatol 2008;3:421-7
   Google Scholar
• Sherman MR, Saifer MGP, Perez-Ruiz F. PEG-uricase in the management of treatment-resistant gout and hyperuricemia. Adv Drug Deliv Rev 2008;60:59-68
   PubMed Web of Science ®Google Scholar
• Sundy JS, Becker MA, Baraf HSB, et al. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (Polyethylene glycol–conjugated uricase) in patients with treatment-failure gout. Results of a phase II randomized study. Arthritis Rheum 2008;58:2882-91
   PubMed Web of Science ®Google Scholar
• Takahashi S, Moriwaki Y, Yamamoto T, et al. Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism. Ann Rheum Dis 2003;62:572-5
   PubMed Web of Science ®Google Scholar
• Wurzner G, Gerster JC, Chiolero A, et al. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens 2001;19:1855-60
   PubMed Web of Science ®Google Scholar
• Richette P, Briere C, Honene-Claviert V, et al. Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study. J Rheumatol 2007;34:1093-8
   Google Scholar
• Huang HY. The effects of vitamin c supplementation on concentrations of uric acid. Results of a randomized controlled trial. Arthritis Rheum 2005;52:1843-7
   PubMed Web of Science ®Google Scholar
• Murthy K, Stevens LA, Stark PC, et al. Variation in the serum creatinine assay calibration: a practical application to glomerular filtration rate estimation. Kidney Intern 2005;68:1884-7
   PubMed Web of Science ®Google Scholar